The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.

PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the ...

Oncogenic KRAS mutations are among the most prevalent driver events in solid tumors, with the KRAS G12D variant constituting the dominant allele in pancreatic ductal adenocarcinoma (PDAC) and a ...

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...

D3 Bio receives US FDA clearance for 2 IND applications to enable phase 1 trial of D3S-003 & phase 2 combo study of elisrasib with D3S-002: Shanghai Thursday, January 22, 2026, 15 ...

The drug is not considered a cure, but results emerging from clinical trials point to the first major advancement in decades for a devastating cancer.

Sotorasib is more cost-effective in treating patients with KRAS G12C non–small cell lung cancer (NSCLC) compared with adagrasib in second- and subsequent-line treatment, accordi ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its potential to improve treatment outcomes. The designation is based on phase 1 ...

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...

Few targets have undergone as dramatic a turnaround as KRAS, one of the most commonly mutated proteins in cancer. For decades KRAS seemed intractable to direct attacks, a teflon target with nowhere ...

Near-80% response rate with KRAS inhibitor fuels predictions of "transformative era" in di ...